SeraNovo is a privately held Dutch pharmaceutical company with a proprietary technology platform to enhance the bioavailability of water insoluble drugs. SeraNovo’s technology harnesses the unique benefits of deep eutectic solvents to create powerful, tailor-made solubility-enhancing formulations that are well tolerated and simple to produce. Since its incorporation in 2017, the company has secured multiple license deals, validating the potential of its technology. SeraNovo has a broad portfolio of programs progressing through clinical phases in 2021 and an established suit of intellectual property.